Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:7:1-3.
doi: 10.1016/j.ctrc.2016.02.006.

Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report

Matthew D Bloom  1 , Joseph M Gibney  1 , Coy D Heldermon  1
Affiliations

Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report

Matthew D Bloom et al. Cancer Treat Commun. 2016.
No abstract available

Keywords: EGFR; lapatinib; pigmentation; tongue.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Tongue discoloration on lapatinib.
See this image and copyright information in PMC

References

    1. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist. 2006;11(10):1047–1057. doi: 10.1634/theoncologist.11-10-1047. - DOI - PubMed
    1. Bilancia D, Rosati G, Dinota A, Germano D, Romano R, Manzione L. Lapatinib in breast cancer. Ann Oncol. 2007;18(suppl 6):vi26–vi30. doi: 10.1093/annonc/mdm220. - DOI - PubMed
    1. Spector NL, Xia W, Burris H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005;23(11):2502–2512. doi: 10.1200/JCO.2005.12.157. - DOI - PubMed
    1. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012;30(21):2585–2592. doi: 10.1200/JCO.2011.35.6725. - DOI - PubMed
    1. Lin NU, Guo H, Yap JT, et al. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I. J Clin Oncol. 2015;33(24):2623–2631. doi: 10.1200/JCO.2014.60.0353. - DOI - PMC - PubMed

LinkOut - more resources